Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Public ClinicalTrials.gov record NCT03600805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
Study identification
- NCT ID
- NCT03600805
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Sarilumab SAR153191 Drug
- Sarilumab matching placebo Drug
- Prednisone Drug
- Prednisone matching placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2018
- Primary completion
- Nov 23, 2020
- Completion
- Nov 23, 2020
- Last update posted
- Mar 27, 2022
2018 – 2020
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400002 | Boca Raton | Florida | 33486 | — |
| Investigational Site Number 8400017 | Gainesville | Florida | 32608 | — |
| Investigational Site Number 8400014 | Iowa City | Iowa | 52242 | — |
| Investigational Site Number 8400018 | Portland | Oregon | 97239 | — |
| Investigational Site Number 8400019 | Philadelphia | Pennsylvania | 19104 | — |
| Investigational Site Number 8400011 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03600805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2022 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03600805 live on ClinicalTrials.gov.